Jefferies Lowers Estimates on Nanosphere

Jun 22, 2011

NEW YORK (GenomeWeb News) – Investment firm Jefferies on Tuesday lowered its revenue and price targets for Nanosphere, following the US Food and Drug Administration's denial of a marketing application for its Plavix (clopidogrel) metabolism test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

This Week in Science

In Science this week: gene regulation changes linked to human brain evolution, and more.

Seven Steps

The New York Stem Cell Foundation's Initiative on Women in Science and Engineering working group presents seven strategies to promote gender equality in the sciences.

Arsenic Adaptation

Researchers link a genetic variation to the ability to quickly process arsenic in people living in the Andes Mountains.

NIPT Tests Find Cancer in Some Pregnant Women

A small portion of pregnant women who've undergone non-invasive prenatal testing have found out from the test that they have cancer.

Featured White Papers

Reducing the variability of pre-analytical handling of biological samples

Main menu